Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com
Santen Pharmaceutical is one of the world’s leading specialist ophthalmic pharmaceutical companies, founded in Japan over a century ago and now serving patients all over the world. We’re the ophthalmology market leader in Japan. We’ve been active in the European market since 1994 and are enjoying strong growth in EMEA (Europe, Middle East, Africa) and worldwide. We’re passionate about improving eye health and vision for patients and making beneficial treatments accessible to patients and healthcare systems. With our sole focus being ophthalmology, we can assess, respond and act quickly in this specialist field where we have deep knowledge and experience.
With our focus on the sense of eyesight, there’s a huge and unique opportunity to improve quality of life for patients while sustaining a strong and effective commercial organisation. As populations age, patient numbers are growing, driven by conditions like glaucoma and retinal disorders. The prescription ophthalmic pharmaceutical market is growing rapidly as new treatment and diagnosis methods emerge from evolving technology. There are significant unmet patient needs in ophthalmology.
Prescription ophthalmic pharmaceuticals are our core business, accounting for over 80% of our global net sales. We also provide over the counter eye treatments and medical devices as well as nutritional products for eye health. In EMEA, we are a leader in glaucoma and dry eye treatment – areas in which our portfolio serves every stage and type of disease. We are also growing our range in eye infections, allergies, and devices for vision correction and glaucoma surgery.
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose.
EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2024 the Company generated consolidated revenue of Euro 26.5 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company’s OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities.
World-Class Quality, Efficacy & Excellence Jamjoom Pharma merges global best practices with local expertise to maximize value creation for key stakeholders, while reinforcing our position as a leading pharmaceutical manufacturing organization in the Middle East and Africa region.
Our strategy is tailored to accelerate and prioritize growth by exploring and expanding into key markets, while creating a positive and lasting impact in the communities we operate in. We strive to optimize operational efficiencies in manufacturing to drive cost reduction and minimize waste, as well as contributing to national and regional self-sufficiency. This enables us to reinforce our position as a key strategic supplier to the Kingdom’s public healthcare system, in line with Vision 2030 and the National Transformation Program.
ESTABLISHED IN 1994, MEDICALS INTERNATIONAL IS A DISTRIBUTOR OF SPECIALIZED MEDICAL AND OPTICAL SUPPLIES TO THE MENA REGION, CYPRUS, GREECE, AZERBAIJAN & TÜRKİYE WITH 19 OFFICES OPERATING REGIONALLY.
Medicals International is headquartered in Lebanon and caters to a wide range of clients including the region’s top tier medical institutions and establishments.
Medicals International has distribution channels dealing in product lines as well as medical equipment in the fields of vision care, ophthalmology, dentistry, and critical care.
Medicals International runs smaller subsidiaries in each of the territories it covers, which creates four major advantages:
With a vast product portfolio of specialized international brands and over 30 years of solid experience in the industry, Medicals International has established itself as one of the leading medical distribution firms in the region.
Established in 1984, AMICO Group is a leading distributor of medical devices across the MENA region, with a footprint in 12 countries. AMICO Group excels in delivering cutting-edge medical technologies in areas such as ophthalmology, orthopedics, neurosurgery, dermatology, general surgery and wound, ENT, Vision Care, spinal surgery and IVD.
AMICO Group distinguishes itself by not only offering the latest in medical technology but also by providing comprehensive medical education and training to specialists. This dual focus ensures that healthcare professionals are well-equipped with the newest innovations to deliver superior patient care. AMICO Group’s dedication to technology, education, and innovation has solidified its status as a trusted partner for healthcare providers throughout the MENA region.
ZEISS is an internationally leading technology enterprise operating in the optical and optoelectronics industries. As a company wholly owned by a foundation, ZEISS is rooted in and committed to responsibility in all its activities. As a pioneer of scientific optics, we continue to challenge the limits of human imagination. With our passion for excellence, we create value for our customers and inspire the world to see in new ways.
The company was founded in 1846 by Carl Zeiss, who anchored precision, a commitment to innovation and the creation of real value for customers and society. In 1889, Ernst Abbe established the Carl Zeiss Foundation in memory of his partner as the sole owner of ZEISS, until today the foundation is exclusively committed to promoting science and progress. As a pioneer of corporate responsibility ZEISS is following a clear path: enabling customers to achieve their goals with value-added solutions developed and manufactured in a responsible manner.
Today, about 45,000 employees globally in around 50 countries work hard to fulfill and exceed customer expectations. They generated annual revenue totaling more than 15 billion euros (FY 2023/24) in the four ZEISS segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology. Currently, 15 percent of revenues are invested in science and R&D. ZEISS believes that innovation and technology are the key to a sustainable future and solutions for global challenges.
In 2002, Carl Zeiss Meditec AG, as it is known today, was created from the merger of the ZEISS Ophthalmology division with Asclepion-Meditec AG, a medical lasers specialist. On 22 July 2002, the Carl Zeiss Meditec AG shares were traded on the Neuer Markt for the first time, making it a publicly traded. Since then, the company has been striving to shape medical progress, efficiency and access to healthcare through innovative technology and support doctors to improve their patients’ quality of life. The Company does this by combining diagnostics technology with therapy and surgical solutions that optimize customers’ workflows to more effectively diagnose and treat diseases. And thus, out of a ZEISS division steeped in optical legacy and a nascent start-up within that division emerged to what is now a world leader in ophthalmology and microsurgery: Carl Zeiss Meditec AG.
Rayner is leading the way in ophthalmic innovation with IOLs and ophthalmic solutions designed to provide surgeons and patients with the best visual outcomes. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.
With more than 70 years of continuous growth and experience, we now sell to over 80 countries. Our mission is to deliver innovative and clinically superior ophthalmic products that consistently respond to the expectations of our global customers and reward the profound trust placed in us to improve sight and quality of life.
Rayner has a broad portfolio of products across the patient pathway, including monofocal and premium Intraocular Lenses (IOLs), Ophthalmic Viscosurgical Devices (OVDs), the Sophi Phaco platform and RayPRO, our patient outcomes digital platform.
RayOne Galaxy, Rayner’s next-generation spiral IOL platform, has been meticulously engineered to redefine the way presbyopia patients experience the world. When patient satisfaction is nonnegotiable, the RayOne Galaxy emerges as a new premium lens solution designed to eliminate dysphotopic compromise.
A proprietary AI engine trained on patient outcomes was used to create a new and unique optical spiral. The resulting design provides optimised visual acuity, a continuous full range of vision, and reduced dysphotopsia.
Rayner’s state-of-the-art global headquarters and manufacturing plant are in Worthing on the South Coast of the UK. Rayner also has regional offices in Berlin, Kuala Lumpur, Lille, Madrid, Milan, Mumbai, New York, Seattle, Sydney and Warsaw.
Rayner is a British company and the only manufacturer of intraocular lenses in the UK.
Italian multinational company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronic acid (HA) in joint care, skin care, eye care, aesthetic care, specialty care and regenerative care. Over 60 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of molecular weight (~1,200 patents). Manufacturing operations – located in Italy – are inspected and approved by major international health authorities, including the US and Korean FDA, the Brazilian ANVISA and G-MED Notified Body, and comply with the strictest international regulations and safety standards. Fidia extends its global reach through local partnersin +120 countries worldwide, as well as wholly owned subsidiaries in USA, Germany, Austria, Spain, France, Russia, Czech Republic, Slovakia, Romania, Poland, Egypt and Middle East.
Fidia has more than 1,600 global employees and boasts a turnover exceeding €463 million (2023), nearly 50
percent of which is generated abroad.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
The Haag-Streit Group, headquartered in Bern, Switzerland, is an internationally operating Swiss medical device company in the field of eye care. Aligned with our motto “Look closer, see further” we are committed to understanding vision for the good of the people.
Working with scientists and physicians for over 160 years, we develop, manufacture, and distribute cutting-edge solutions globally. Focused on ophthalmology, our broad portfolio spans general and specialty diagnostics, surgical microscopes, simulators for medical education, and software. Together with our partners around the world, the Haag-Streit Group also offers cutting-edge solutions such as tonometers, and a wide range of ophthalmic furniture for the refractive workplace.
We are proud to develop innovative and progressive solutions of the highest quality for eye care specialists.
Learn more: www.haag-streit.com
SOLMED is a private company that supplies the latest ophthalmic diagnostic tools, treatment solutions, and surgical instruments across the healthcare sector in the Middle East and Africa. Since its founding in 2008, SOLMED has redefined eye-care standards. We remain true to our founding belief and have broadened our vision to establish SOLMED as the benchmark provider of high quality ophthalmic products.
For over 30 years, UFSK-International OSYS has been a leading developer of highly specialized mobile surgical tables and operating room chairs for ophthalmology. Our owner-managed company, led by Jürgen Scherrieble, is dedicated to combining technical innovation with international expertise. We are committed to delivering high-quality medical devices while fostering a work environment built on trust and respect. Our focus remains on medical progress and customer-driven solutions that enhance surgical efficiency worldwide.
At UFSK-International OSYS, we believe in developing products by practitioners, for practitioners. Our mission is to provide ergonomic, durable, and service-friendly surgical solutions that meet the high patient throughput demands of ophthalmology. By working closely with renowned international ophthalmic surgeons, we ensure that our products are tailored to the real-world needs of medical professionals.
Our vision is to set new standards in ophthalmic surgical equipment by integrating cutting-edge technology with practical application, enabling efficient and safe surgical procedures worldwide.
We are a leading Manufacturer and Exporter of Micro Ophthalmic Surgical Instruments. Our Quality management system is certified with ISO 13485:2016 and our product also Europium standard. Our Quality control system is under strict supervision of technical experts.
PLUS SURGICALS was established with a mission to serve our beloved as respected customers more better by supplying best quality Stainless Steel and Titanium instruments. Our Quality instruments are exporting many countries all over the world. We are a regular participant of All India Ophthalmological Society conferences and all State ophthalmic societies of INDIA and many more in the foreign countries including American Academy Conferences.
FGMED, First Global Medical Equipment LLC, is a specialized ophthalmic company, head quartered in Dubai.
Founded in 2014 and proudly serving all ophthalmic specialized centres and hospitals across UAE with the most advanced equipment and high quality products.
Since 1895, OCULUS has been a trusted partner to eye care professionals around the world.
With a deep commitment to precision and innovation, every OCULUS device is designed and manufactured with care at our headquarters in Germany.
Visit us at our booth to explore the Pentacam® Cornea OCT – the first device to combine Scheimpflug Tomography with OCT technology, uniquely designed for cornea specialists!
We will also be showcasing the Pentacam® AXL Wave and Corvis® ST.
Since its inception in 1992, Aurolab has established itself as a pioneering force in global ophthalmic care, delivering quality and innovation in comprehensive vision solutions. As one of the world’s leading manufacturers of intraocular lenses, Aurolab supports eye care professionals across the globe, providing over 200 advanced solutions crafted to improve patient treatment and outcomes.
Through an integrated ecosystem, Aurolab delivers a range of state-of-the-art diagnostic equipment, high-precision surgical tools, intraocular lenses (IOLs), and therapeutic solutions. This ecosystem empowers professionals and optimizes patient care, reinforcing Aurolab’s dedication to advancing ophthalmology.
Driven by the values of accessibility and quality, Aurolab’s products reach millions worldwide, transforming lives by enhancing access to premium eye care. By continually innovating and expanding its offerings, Aurolab strives to cultivate new possibilities for patients and professionals alike, setting a benchmark in vision care solutions globally.
Laboratoires KÔL is a new generation French pharmaceutical company founded in February 2020.
Our mission is to provide the best innovative pharmaceutical solutions for unmet needs in rare cornea diseases.
Laboratoires KÔL currently markets two pharmaceutical products with Compassionate Access Authorization. These derogatory authorizations are intended to make products available to patients with rare and serious diseases for which there is no therapeutic alternative.
In collaboration with our local partner these products are available in the UAE and Qatar.
Optomed is a Finnish medical technology company and a leading provider of handheld fundus cameras. Our AI-powered screening solutions aim to transform diagnostic processes of various diseases, empower early detection, and to improve people’s health through innovations. Two decades of pioneering expertise, we design cutting-edge retinal imaging technology that is trusted by healthcare professionals worldwide. Our technology is extensively patented, clinically validated and has approvals in all key markets, including CE, FDA and CFDA.
Optomed Aurora® IQ is a clinically validated non-mydriatic handheld camera that brings high-quality retinal and anterior segment imaging anywhere. For efficiency in screening, the camera includes an optional AI analysis that delivers the screening result to the camera display, on the spot.
Optomed – Enabling Screening for All
Théa is a pioneering independent European pharmaceutical company, dedicated to the research, development, and commercialization of innovative eye care solutions. With more than 30 years of expertise, Théa has become a leader in the field of eye care, offering a wide range of products that address the diverse needs of eye care professionals, pharmacists, and their patients. Headquartered in Clermont-Ferrand, France, this family-owned company is present in 75 countries worldwide. Its subsidiary, Théa Middle East, has been actively supporting the ophthalmology scientific community in the region for more than 10 years. Théa continues to lead worldwide in ophthalmic innovation, committed to improving the quality of life for patients through cutting-edge solutions in eye care.
Founded in the United Arab Emirates in 2017 by a private and professional proprietor. Euyuncare is a trading company of Ophthalmic equipment, Implantable Phakic Contact Lens and EDOF IOLs, Low Vision Aid Devices and Technology, Instruments, Ophthalmic Consumables, Human Tissue and Special Contact Lenses.
We are dedicated to build and establish relationships with manufacturers of leading technology in the optical industry.
We are committed to delivering high-quality ophthalmic products and solutions coupled with exceptional service. We have expanded to become a market leading trading companies that provides high-quality care and cost-effective ophthalmic products & correction solutions within our portfolio of hospitals, clinics and medical centers in the UAE.
Excellent hi-care was established in 1995 manufacturing and marketing of Intraocular lenses and ophthalmic surgical products. (Implantable Contact Lens(ICL), Toric Hydrophobic and Hydrophilic Lens, Trifocal Hydrophobic and Hydrophilic Lens, Multifocal Hydrophobic and Hydrophilic Lens, Opthalmic Solution Lens,Hydrophobic Foldable Intraocular lenses, 360 degree Hydrophilic Acrylic Foldable IOLs, PMMA Single Piece IOls and Ophthalmic knives/blades). The products are manufacturing as per Good manufacturing practices with state of the art technology. Our products are well recognized and using in leading eye care institutions and ophthalmologists in more than 35 countries worldwide.
Our company complies ISO 13485:2016 quality management systems and most of our products are CE certified to confirming the products are manufactured as per international quality standards.
SO has been a global leader in diagnostic ophthalmic instruments for over fifty years. Since its inception, the company has experienced continuous growth, driven by the visionary leadership of its founders, Mr. Sergio Mura and Mr. Giuseppe Matteuzzi. Under their guidance, CSO has expanded its market presence, becoming an undisputed leader in the industry.
Recently, CSO has further advanced its capabilities by expanding its manufacturing facilities with new production lines and enhancing its R&D department by recruiting additional engineers and software developers.
With a highly efficient and widespread team of employees and sales representatives, CSO has established itself as a strong player in the international market.
Among its most innovative products are the MS-39 and OSIRIS, which set new standards in diagnostic technology. The MS-39 is a state-of-the-art OCT device combined with a Placido disk corneal topographer, offering unparalleled precision in anterior segment tomography. It is considered one of the most advanced solutions for corneal and anterior segment analysis, ensuring exceptional accuracy for a wide range of clinical applications.
The OSIRIS aberrometer, equipped with groundbreaking PWS technology, enables highly detailed wavefront analysis by capturing up to 45,000 points, providing eye care professionals with an unmatched level of diagnostic information for personalized treatments.
In addition to these flagship products, CSO offers other instruments such as the COBRA+, an advanced and user-friendly fundus camera, the SIRIUS+, a combination of a Scheimpflug camera and corneal topographer, representing the forefront of corneal tomography. The company has also upgraded all of its slit lamps and the PERSEUS endothelial microscope with LED light sources.
CSO’s product portfolio continues to grow with newly designed refraction units made from innovative materials, complemented by a wide selection of chairs and drawer units.
CSO’s quality management system is certified according ISO 13485 standards
The company’s success is driven by its commitment to technological innovation, the refinement of Italian design, the reliability and efficiency of its production processes, a highly skilled workforce, and a deep dedication to customer safety. These principles form the foundation of CSO’s production philosophy and are key to its long-standing leadership in the ophthalmic industry
Established in 1989, Zahrawi Group is a pioneer Medical Devices and Life Science Distributor in the Gulf region, with a presence in UAE, KSA, Qatar, Oman, and Bahrain. Zahrawi Group is specialized in Surgical, Medical, Nuclear Medicine, Diagnostic, and Analytical Lab solutions, and was founded with a vision to be the leading and most trusted partner in the GCC.
Zahrawi Group is committed to improving people’s lives by introducing innovative Healthcare products, Smart solutions, and Outstanding services.
We are a market-leading pharma and biotechnology company, based in Switzerland and operating around the world.
For over 30 years, we have been successfully developing, producing, and promoting APIs, pharmaceutical products, and medical devices in Ophthalmology.
Our medium-sized company backed up by an exclusive network of subsidiaries, agents, and partners makes us efficient and responsive in the market, with the ability to develop custom solutions for patients and partners. As family firm since our foundation, we have strong values that are shared by everyone from the boardroom to the factory.
alfadiag is a leading provider of innovative diagnostic solutions offering a comprehensive range of products and services designed to revolutionize the healthcare sector. We specialize in cutting-edge technologies, including AI-powered medical diagnostics, and Next Generation Sequencing (NGS), to support healthcare professionals in delivering precise, personalized, and efficient diagnoses and treatment. Committed to innovation and excellence, alfadiag is dedicated to enhancing patient care through state-of-the-art tools and personalized support.
Kanghua is a leading manufacturer for ophthalmic devices which was established in 1996.
We provide multiple options enable opthalmologists and optometrists to serve the patients better.
We dedicated to R&D, manufacturing and distributing devices such as slit lamp, dry eye analyzer and treatment, ultrasound AB scan, fundus camera, perimeter.
We certified by CE and FDA.
We offer world-class quality with our efforts, help our customers to creat more value.
Our vision is simple. We innovate to improve the lives of ophthalmologists and patients worldwide. We’re dedicated and passionate about addressing the needs of ophthalmologists and improving practice efficiency, patient care and physician convenience.
We also believe that no one can achieve this on their own, which is why we work closely with a network of ophthalmologists and industry leaders. Together, we can change ophthalmic care for the better.
Vision Share is a is a non-profit member organization of U.S. Eye Banks, and a Trusted Source for Corneal Transplant and Research Tissue for more than 27 years. Vision Share facilitates the distribution and client support of donor corneas and research tissue across the United States and in over 30 countries. To date, Vision Share has supplied over 138,000 corneas, worldwide. All Vision Share eye bank members are accredited by the Eye Bank Association of America (EBAA) and registered with the Food and Drug Administration (FDA).
Mission: Provide ocular tissue with exceptional service and support global sight restoration.
Sign up now to our newsletter
